Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
Northwestern Medicine scientists have discovered that targeting neuronal signaling controlling aberrant learning in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback